期刊
AMERICAN JOURNAL OF CARDIOLOGY
卷 108, 期 6, 页码 888-891出版社
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjcard.2011.05.012
关键词
-
资金
- Abbott Cardiovascular Systems Inc., Santa Clara, California
- Accumetrics, Inc., San Diego, California
- AstraZeneca, Wilmington, Delaware
- Boston Scientific Corporation, Natick, Massachusetts
- Bristol-Myers Squibb, New York, New York
- Cordis Corporation, a Johnson & Johnson Company, Bridge-water, New Jersey
- Hoffman-La Roche, Inc., Nutley, New Jersey
- Eli Lilly & Company, Indianapolis, Indiana
- MEDRAD, Inc., Warrendale, Pennsylvania
- MD Scientific, LLC, Charlotte, North Carolina
- Medtronic Vascular, Inc., Santa Rosa, California
- Sanofi-Aventis, Malvern, Pennsylvania
- Schering Plough Research Institute, a Division of Schering Corporation, Kenilworth, New Jersey
- Spectranetics Corporation, Colorado Springs, Colorado
The precise cause of takotsubo cardiomyopathy (TC) remains controversial. Plaque rupture with transient thrombotic occlusion of a transapical left anterior descending coronary artery (LAD) has been advanced as a potential mechanism. To explore this hypothesis, the investigators analyzed data from 11 patients prospectively enrolled in the Rhode Island Takotsubo Cardiomyopathy Registry who underwent coronary angiography and intravascular ultrasound evaluation of the LAD during their initial presentation. Despite the presence of nonobstructive coronary artery disease, no culprit lesion was identified in any patient. Similarly, the course of the LAD failed to account for the characteristic left ventricular apical ballooning seen in TC. In conclusion, an atherosclerotic coronary lesion in the LAD causing an aborted myocardial infarction may not be the primary underlying cause of TC, and nonobstructive coronary artery disease and TC may coexist without a direct causal association. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;108:888-891)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据